BCL2 inhibition venetoclax has demonstrated robust single-agent activity in t(11;14) MM that harbor high expression of antiapoptotic protein BCL-2, which can be evaluated in t(11;14) with cardiac amyloidosis as well in the future (31). This evidence concerns the gene BCL2 and cardiac amyloidosis.